Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics
This article was originally published in PharmAsia News
Executive Summary
Merck KGaA has committed up-front payments and research funding of up to $10 million to Archemix to collaborate on the development and commercialization of first-in-class aptamer-based drugs to treat cancer